Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2009

Open Access 01-12-2009 | Review

Institutional shared resources and translational cancer research

Author: Paolo De Paoli

Published in: Journal of Translational Medicine | Issue 1/2009

Login to get access

Abstract

The development and maintenance of adequate shared infrastructures is considered a major goal for academic centers promoting translational research programs. Among infrastructures favoring translational research, centralized facilities characterized by shared, multidisciplinary use of expensive laboratory instrumentation, or by complex computer hardware and software and/or by high professional skills are necessary to maintain or improve institutional scientific competitiveness. The success or failure of a shared resource program also depends on the choice of appropriate institutional policies and requires an effective institutional governance regarding decisions on staffing, existence and composition of advisory committees, policies and of defined mechanisms of reporting, budgeting and financial support of each resource. Shared Resources represent a widely diffused model to sustain cancer research; in fact, web sites from an impressive number of research Institutes and Universities in the U.S. contain pages dedicated to the SR that have been established in each Center, making a complete view of the situation impossible. However, a nation-wide overview of how Cancer Centers develop SR programs is available on the web site for NCI-designated Cancer Centers in the U.S., while in Europe, information is available for individual Cancer centers. This article will briefly summarize the institutional policies, the organizational needs, the characteristics, scientific aims, and future developments of SRs necessary to develop effective translational research programs in oncology.
In fact, the physical build-up of SRs per se is not sufficient for the successful translation of biomedical research. Appropriate policies to improve the academic culture in collaboration, the availability of educational programs for translational investigators, the existence of administrative facilitations for translational research and an efficient organization supporting clinical trial recruitment and management represent essential tools, providing solutions to overcome existing barriers in the development of translational research in biomedical research centers.
Literature
1.
Hait W: Sustaining the clinical in clinical translational research. Clin Cancer Res. 2006, 12: 1-2.PubMed
2.
Pober JS, Neuhauser CS, Pober JM: Obstacles facing translational research in academic medical centers. FASEB J. 2001, 15: 2303-2313.PubMed
3.
4.
Angeletti RH, Bonewald LF, De Jongh K, Niece R, Rush J, Stults J: Research Technologies: fulfilling the promise. FASEB J. 1999, 13: 595-601.PubMed
5.
Howells J, James A, Malik K: The sourcing of technological knowledge: distributed innovation processes and dynamic change. R&D Management. 2003, 4: 395-409.
6.
7.
8.
9.
10.
Berns KI, Bond EC, Manning F: Resource Sharing in Biomedical Research. 1996, Washington DC: National Academy of Sciences
11.
12.
Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol. 2004, 172: 2731-2738.PubMed
13.
Schnabel J: Neuroscience. Standard model. Nature. 2008, 45: 682-685.
14.
Pierce MC, Javier DJ, Richards-Kortum R: Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer. 2008, 123: 1979-1990.PubMedCentralPubMed
15.
Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukumura D, Jain RK: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med. 2001, 7: 864-868.PubMed
16.
Kelloff GJ, Sigman CC: New science-based endpoints to accelerate oncology drug development. Eur J Cancer. 2005, 41: 491-501.PubMed
17.
Ke S, Wen X, Gurfinkel M, Charnsagavej C, Wallace S, Sevick-Muraca EM, Li C: Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003, 63: 7870-7875.PubMed
18.
Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla Favera R: Non transcriptional control of DNA replication by c-myc. Nature. 2007, 448: 445-451.PubMed
19.
Conchello JA, Lichtman JW: Optical sectioning microscopy. Nat Methods. 2005, 2: 920-931.PubMed
20.
21.
Perfetto SP, Chattopadhyay P, Rodererer M: Seventeen-color flow cytometry: unravelling the immune system. Nat Rev Immunol. 2004, 4: 648-655.PubMed
22.
Stacey DW, Hitomi M: Cell cycle studies based upon quantitative image analysis. Cytometry A. 2008, 73: 270-278.PubMed
23.
Kutzik PO, Irish JM, Nolan GP, Perez OD: Analysis of protein phosphorylation and cellular signaling events by flow cytometry. Clin Immunol. 2004, 110: 206-221.
24.
Schakney SE, Shankey TV: Common patterns of genetic evolution in solid tumors. Cytometry. 1997, 29: 1-27.
25.
Irish JM, Kotecha N, Nolan GP: Mapping normal and cancer cell signaling networks: towards single-cell proteomics. Nat Rev Cancer. 2006, 6: 146-155.PubMed
26.
Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008, 111: 3941-3967.PubMed
27.
Freeman SD, Jovanovic JV, Grimwade D: Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol. 2008, 35: 388-400.PubMed
28.
Kern F, LiPira G, Gratama JW, Manca F, Roederer M: Measuring Ag specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol. 2005, 26: 477-484.PubMed
29.
Sklar LA, Carter MB, Edwards BS: Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening. Curr Opin Pharmacol. 2007, 7: 527-534.PubMedCentralPubMed
30.
Nolan JP, Mandy F: Multiplexed and microparticle-based analyses: quantitative tools for the large scale-analysis of biological systems. Cytometry A. 2006, 69: 318-325.PubMedCentralPubMed
31.
Sachdeva N, Asthana D: Cytokine quantitation: technologies and applications. Front Biosci. 2007, 12: 4682-4695.PubMed
32.
Lu J, Getz G, Miska A, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert B, Mak R, Ferrando A, Downing J, Jacks T, Horviz R, Golub T: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838.PubMed
33.
Eisenstein M: Cell sorting: divide and conquer. Nature. 2006, 441: 1179-1185.PubMed
34.
Ibrahim SF, Engh van der G: Flow cytometry and cell sorting. Adv Biochem Eng Biotechnol. 2007, 106: 19-39.PubMed
35.
Johnson LA, Welch GR, Keyvanfar K, Dorfmann A, Fugger EF, Schulman JD: Gender preselection in humans? Flow cytometric separation of X and Y spermatozoa for the prevention of X-linked diseases. Hum Reprod. 1993, 8: 1733-1739.PubMed
36.
Cram LS, Bell CS, Fawcett JJ: Chromosome sorting and genetics. Methods Cell Sci. 2002, 24: 27-35.PubMed
37.
Chung CH, Levy S, Chaurand P, Carbone DP: Genomics and proteomics: emerging technologies in clinical cancer research. Crit Rev Oncol Hematol. 2007, 61: 1-25.PubMed
38.
Quackenbush J: Microarray analysis and tumor classification. N Engl J Med. 2006, 354: 2463-2472.PubMed
39.
Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenkoi O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I: Micro RNA accurately identify cancer tissue origin. Nat Biotechnol. 2008, 26: 462-469.PubMed
40.
Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005, 365: 488-492.PubMed
41.
Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Gracia JG, Georghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackensbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W: Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005, 2: 345-350.PubMed
42.
Yauk CL, Berndt ML: Review of the literature examining the correlation among DNA microarray technologies. Environ Mol Mutagen. 2007, 48: 380-394.PubMedCentralPubMed
43.
de Reynies A, Geromin D, Cayuela JM, Petel F, Dessen P, Sigaux F, Rickman DS: Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC Genomics. 2006, 7: 51-PubMedCentralPubMed
44.
Cowell JK, Hawthorn L: The application of microarray technology to the analysis of cancer genome. Curr Mol Med. 2007, 7: 103-120.PubMed
45.
Strausberg RL, Levy S, Rogers YH: Emerging DNA sequencing technologies for human genomic medicine. Drug Discov Today. 2008, 13: 569-577.PubMed
46.
Shendure J, Ji H: Next-generation DNA sequencing. Nat Biotechnol. 2008, 26: 1135-1145.PubMed
47.
Speicher MR, Carter NP: The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005, 6: 782-792.PubMed
48.
Lambros MB, Natrajan R, Reis-Filho JS: Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007, 38: 1105-1122.PubMed
49.
Hsi BL, Xiao S, Fletcher JA: Chromogenic in situ hybridization and FISH in pathology. Methods Mol Biol. 2002, 204: 343-351.PubMed
50.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutoviz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic abnalysis of solid tumors. Science. 1992, 258: 818-821.PubMed
51.
Maciejewsi JP, Mufti GJ: Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008, 112: 965-974.
52.
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008, 5: 621-628.PubMed
53.
Shendure J: The beginning of the end of microarrays?. Nat Methods. 2008, 5: 585-587.PubMed
54.
Rhoades A: Molecular Pathology. Its integration in the routine laboratory. The Biomedical Scientist. 2006, 8: 714-718.
55.
Camp RL, Neumeister V, Rimm DL: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008, 26: 5630-5637.PubMed
56.
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robison A, Gelmon K, Huntsman D, Camp RL, Rimm DL, American Society of Clinical Oncology; College of American Pathologists: Quantititive justification of the change from 10% to 30% for human EGFR2 scoring in the ASCO/AAP guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol. 2007, 25: 5418-5425.PubMed
57.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montjie JE, Shah R, Pienta KJ, Rubin MA, Channayan AM: Recurrent fusions of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005, 310: 644-648.PubMed
58.
59.
Owens SR, Greenson JK: Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol. 2007, 31: 285-290.PubMed
60.
Perou CM, Sorlie T, Eisen MB, Rijn van der M, Jeffrey SS, Rees CA, Pollack JK, Ross DT, Johnsen H, Aksien LA, Fluge O, Pergamenschikov A, Williams C, Zhu S, Lenning P, Borresen-Dale A, Brown P, Botstein D: Molecular portraits of human breast cancer. Nature. 2000, 406: 747-752.PubMed
61.
Espina V, Heiby M, Pierobon M, Liotta MA: Laser capture microdissection technology. Expert Rev Mol Diagn. 2007, 7: 647-657.PubMed
62.
Rodrigues AS, Espina BH, Espina V, Liotta LA: Automated laser capture microdissection for tissue proteomics. Methods Mol Biol. 2008, 441: 71-90.
63.
Hergenhahn M, Kenzelmann M, Grohne HJ: Laser-controlled microdissection of tissues opens a window for new opportunities. Pathol Res Pract. 2003, 199: 419-423.PubMed
64.
Kolch W, Mischak H, Pitt AR: The molecular make-up of a tumor: proteomics in cancer research. Clin Sci (Lond). 2005, 108: 369-383.
65.
Petrocoin EF, Biechsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishmann D, Sgoi DC, Munson PJ, Esserman LJ, Liotta LA: Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005, 23: 3614-3621.
66.
Lin J, Li M: Molecular profiling in the age of cancer genomics. Expert Rev Mol Diagn. 2008, 8: 263-276.PubMed
67.
Omenn GS: Strategies for plasma proteomic profiling of cancers. Proteomics. 2006, 6: 5662-5673.PubMed
68.
Wulfkuhle J, Espina V, Liotta L, Petricoin E: Genomic and proteomic technologies for individualization and improvement of cancer treatment. Eur J Cancer. 2004, 40: 2623-2632.PubMed
69.
Hager JW: Recent trends in mass spectrometer development. Anal Bioanal Chem. 2004, 378: 845-850.PubMed
70.
Gorelik E, Landsittel D, Marrangoni A, Modugno F, Velikokhatnaya L, Winans M, Bigbee W, Herberman R, Loksin A: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 981-987.PubMed
71.
Pelech S: Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr Pharm Biotechnol. 2004, 5: 69-77.PubMed
72.
Frese KK, Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer. 2007, 7: 645-658.PubMed
73.
van Dyke T, Jacks T: Cancer modeling in the modern era: progress and challenges. Cell. 2002, 108: 135-144.PubMed
74.
Hanahan D, Wagner EF, Palmiter RD: The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007, 21: 2258-2270.PubMed
75.
Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ: Small animal imaging. Current technology and perspectives for oncological imaging. Eur J Cancer. 2002, 38: 2173-2188.PubMed
76.
Weissleder R: Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer. 2002, 2: 11-18.PubMed
77.
Olive KP, Tuveson DA: The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006, 12: 5277-5287.PubMed
78.
Kherlopian AR, Song T, Duan Q, Neimark M, Po MJ, Gohagan JK, Laine AF: A review of imaging techniques for system biology. BMC Syst Biol. 2008, 2: 74-PubMedCentralPubMed
79.
Pittet MJ, Mempel TR: Regulation of T-cell migration and effector functions: insights from in vivo imaging. Immunol Rev. 2008, 221: 107-129.PubMed
80.
Nyman HAT, Kristensen AT, Flagstad A, McEvoy FJ: A review of sonographic assessment of tumor metastases in liver and superficial lymph nodes. Vet Radiol Ultrasound. 2004, 45: 438-448.PubMed
81.
Riegman PH, Dinjens WN, Oosterhius JW: Biobanking for interdisciplinary clinical research. Pathobiology. 2007, 74: 239-244.PubMed
82.
Morente MM, Alonso S: Current challenges of human tumor banking. Hematol Oncol. 2005, 23: 54-56.PubMed
83.
Barnes RO, Parisien M, Murphy LC, Watson PH: Influence of evolution in tumor banking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev. 2008, 17: 3344-3350.PubMed
84.
International Society for Biological and Environmental Repositories: Best practices for repositories I: collection, storage, and retrieval of human biological materials for research. Cell Preservation Technology. 2005, 3: 5-20.
85.
van Veen EB, Riegman P, Dinjens W, Lam K, Oomen MH, Spaz A, Mager R, Ratcliffe C, Knox K, Kerr D, van damme B, vijver van der M, van Boven H, Morente MM, Alonso S, kerjaski D, Pammer J, Lopez-Guerrero J, Llombart Bosch A, carbone A, Gloghini A, Teodorovic I, Isabelle M, Passoiukov A, Lejeune S, Therasse P, Oosterhius JW: TuBaFrost3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer. 2006, 42: 2914-2923.PubMed
86.
87.
De Paoli P: Biobanking in microbiology: from sample collection to epidemiology, diagnosis and research. FEMS Microbiol Rev. 2005, 29: 897-910.PubMed
88.
Qualman SJ, France M, Grizzle WE, LiVolsi VA, Moskaluk CA, Ramirez NC, Washington MK: Establishing a tumor bank: banking, informatics and ethics. Br J Cancer. 2004, 90: 1115-1119.PubMedCentralPubMed
89.
Yuille M, van Ommen G, Brechot C, Cambon-Thomsen A, Dagher G, Landegren U, Litton JE, Pasterk M, Pletonen L, Taussig M, Wichmann HE, Zatloukal K: Biobanking in Europe. Brief Bioinform. 2008, 9: 14-24.PubMed
90.
Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V, Hallmans G, Jellum E, Jousilahti P, Knekt P, Koskela P, Kyyronen P, Lenner P, Loustarinen T, Love A, Ogsmundottir H, Stattin P, Tenkanen L, Tryggvadottir L, Virtamo J, Wadell G, Widell A, Lehtinen M, Dillner J: Nordic biological specimen banks as basis for studies of cancer causes and control-more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol. 2007, 46: 286-307.PubMed
91.
Tedeschi R, Luostarinen T, De Paoli P, Gislefoss RE, Tenkanen L, Virtamo J, Koskela P, Hallmans G, Lehtinen M, Dillner J: Joint Nordic prospective study on HHV-8 multiple myeloma risk. Br J Cancer. 2005, 93: 834-837.PubMedCentralPubMed
92.
Knox K, Kerr DJ: Establishing a national tissue bank for surgically harvested cancer tissue. Br J Surg. 2004, 91: 134-136.PubMed
93.
Zika E, Schulte in der Baumen T, Kaye J, Brand A, Ibarreta D: Sample, data use and protection in biobanking in Europe: legal issues. Pharmacogenomics. 2008, 9: 773-781.PubMed
94.
95.
96.
Ermolaeva O, Rastogi M, Pruitt KD, Schuler GD, Bittner ML, Chen Y, Simon R, Meltzer P, Trent JM, Boguski MS: Data management and analysis for gene expression arrays. Nat Genet. 1998, 20: 19-23.PubMed
97.
Kanehisa M, Bork P: Bioinformatics in the post sequence era. Nat Genet. 2003, 33 (Suppl): 305-310.PubMed
98.
Simon R: The use of genomics in clinical trial design. Clin Cancer Res. 2008, 14: 5984-5993.PubMed
99.
Gomez-Lopez G, Valencia A: Bioinformatics and cancer research: building bridges for translational research. Clin Transl Oncol. 2008, 10 (2): 85-95.PubMed
100.
Nguyen DX, Massaguè J: Genetic determinants of cancer metastasis. Nat Rev Genet. 2007, 8: 341-352.PubMed
101.
102.
Anderson KC: Setting the standard for translational cancer metastasis. Clin Cancer Res. 2009, 1: 1-
103.
George SL: Statistical issues in translational cancer research. Clin Cancer Res. 2008, 14: 5954-5958.PubMed
104.
Vickers AJ, Jang K, Sargent D, Lilja H, Kattan MW: Systematic review of statistical methods used in molecular marker studies in cancer. Cancer. 2008, 112: 1862-1868.PubMedCentralPubMed
105.
Owzar K, Barry WT, Jung SH, Sohn I, George SL: Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res. 2008, 14: 5959-5966.PubMedCentralPubMed
106.
Olopade OI, Grusko TA, Nanda R, Huo D: Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008, 14: 7988-7999.PubMedCentralPubMed
107.
Tortora G, Ciardiello F, Gasparini G: Combined targeting of EGFR-dependent VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol. 2008, 5: 521-530.PubMed
108.
109.
110.
Workman P, Aboagye E, Chung Y, Griffiths J, Hart R, Leach M, Maxwell R, McSheehy P, Prioce P, Zweit J: Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006, 98: 580-598.PubMed
111.
Roses AD: Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008, 7: 807-817.PubMed
112.
Yong WP, Innocenti F, Ratain M: The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006, 62: 35-46.PubMedCentralPubMed
113.
American Society of Clinical Oncology: American Society of Clinical Oncology policy statement. Oversight of clinical research. J Clin Oncol. 2003, 21: 2377-2386.
114.
Dilts DM, Sandler AB: Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006, 24: 4545-4552.PubMed
115.
Zwelling LA, Brunell CA: Strategies for the administration of a clinical trials infrastructure: lessons from a comprehensive cancer center. Cancer Treat Res. 2007, 132: 241-274.PubMed
116.
Moses H, Martin JB: Academic relationships with industry: a new model for biomedical research. JAMA. 2001, 285: 933-935.PubMed
117.
Plotkin SA: Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008, 47: 401-409.PubMed
118.
119.
Hamilton DH, Bretscher PA: Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer. Cancer Immunol Immunother. 2008, 57: 1125-1136.PubMed
120.
Chaussabel D, Quinn C, Shan J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejas A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski K, Whiote P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V: A modular analysis framework for blood genomic studies:application to systemic lupus erythematosus. Immunity. 2008, 29: 150-164.PubMedCentralPubMed
121.
Heng TS, Painter MW: The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008, 9: 1091-1094.PubMed
122.
Girnita DM, Burkart G, Zeevi A: Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Curr Opin Immunol. 2008, 20: 614-625.PubMedCentralPubMed
123.
124.
Gee AP: Regulatory issues in cellular therapies. Expert Opin Biol Ther. 2003, 3: 537-540.PubMed
125.
126.
127.
Rebulla P, Lecchi L, Lazzari L, Giordano R, Porretti L, Giovanelli S, Salvaterra E, Clerici L, Baldocchi G: Development of a biological resource center for cellular therapy and biobanking in a public polyclinic university hospital. Biologicals. 2008, 36: 79-87.PubMed
128.
McKenna DH, Kadidio DM, Miller JS, Orchard P, Wagner J, McCullogh J: The Minnesota Molecular and Cellular Therapeutics Facility: a state of the art biotherapeutics engineering laboratory. Transfus Med Rev. 2005, 19: 217-228.PubMed
129.
130.
Liu SK, Olive PL, Bristow R: Biomarkers of DNA DSB inhibitors and radiotherapy in clinical trials. Cancer Metastasis Rev. 2008, 27: 445-458.PubMed
Metadata
Title
Institutional shared resources and translational cancer research
Author
Paolo De Paoli
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-7-54

Other articles of this Issue 1/2009

Journal of Translational Medicine 1/2009 Go to the issue

Research

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Review

Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful

Research

A novel role of HLA class I in the pathology of medulloblastoma

Research

Can urinary exosomes act as treatment response markers in prostate cancer?

Research

High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis

Research

Human fallopian tube: a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits